MD430C2 - Method for human leucocytar interferone preparation - Google Patents

Method for human leucocytar interferone preparation

Info

Publication number
MD430C2
MD430C2 MD95-0076A MD950076A MD430C2 MD 430 C2 MD430 C2 MD 430C2 MD 950076 A MD950076 A MD 950076A MD 430 C2 MD430 C2 MD 430C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
leucocytar
interferone
preparation
Prior art date
Application number
MD95-0076A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Van Norman Goeddel David
Pestka Sidney
Original Assignee
F.Hoffmann-La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag, Genentech, Inc. filed Critical F.Hoffmann-La Roche Ag
Publication of MD430C2 publication Critical patent/MD430C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Application field: genetic engineering, leucocytar interferone preparation. The summary of the invention: the method comprises the DNA sequence detection and isolation and recombinant molecules construction, coding the polypeptide which possesses the immunologic and biologic activity of HIFN-α. there are obtained recombinant plasmide DNA, containing the Z-pBR 322 (Pst)HCIF-4c, Z-pBR 322 (Pst), HIF-2h, Z-pBR 322 (Pst) HcIF-SN-35, Z-pBR 322 (Pst) Hc1F-SN-42, Z-pKT287 (Pst) Hc1F-2h-AH6 DNA sequence as well as the sequences which are hybridizated with the mentioned insertions.
MD95-0076A 1980-07-01 1994-12-30 Method for human leucocytar interferone preparation MD430C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16498680A 1980-07-01 1980-07-01
US18490980A 1980-09-08 1980-09-08
US20557880A 1980-11-10 1980-11-10
US06/256,204 US6610830B1 (en) 1980-07-01 1981-04-21 Microbial production of mature human leukocyte interferons

Publications (1)

Publication Number Publication Date
MD430C2 true MD430C2 (en) 1996-06-30

Family

ID=27389083

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0076A MD430C2 (en) 1980-07-01 1994-12-30 Method for human leucocytar interferone preparation

Country Status (6)

Country Link
US (2) US6610830B1 (en)
KR (1) KR860001558B1 (en)
CA (1) CA1341583C (en)
GE (1) GEP20074163B (en)
MD (1) MD430C2 (en)
ZW (1) ZW14781A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JP2003530838A (en) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド Albumin fusion protein
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
EP2292652A2 (en) * 2000-11-03 2011-03-09 Pestka Biomedical Laboratories, Inc. Interferons uses and compositions related thereto
FR2822845B1 (en) * 2001-03-30 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES
JP2005517648A (en) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド Compositions and methods for treating hepatitis virus infections
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2003256125A1 (en) * 2002-08-31 2004-03-19 Cj Corp. Glycosylated human interferon alpha isoform
DE60332358D1 (en) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
PL396711A1 (en) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Polymer conjugates with cytokines, chemokines, growth factors, polypeptide hormones and their antagonists, the pharmaceutical composition and method of prevention, diagnosis or treatment
RS20050502A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
US7318918B2 (en) * 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
BRPI0609809A2 (en) * 2005-05-18 2011-10-11 Maxygen Inc isolated or recombinant polypeptide, conjugate, composition, isolated or recombinant polynucleotide, host cell, vector, methods for preparing the polypeptide, for preparing a conjugate, for inhibiting virus replication in virus-infected cells to reduce the number of copies of a virus in virus-infected cells, to reduce hcv rna level in serum of an hcv infected patient, to reduce hbv dna level in serum of an hbv infected patient, and to reduce hiv rna level in serum from an HIV-infected patient, and use of the polypeptide or conjugate
KR20080021614A (en) * 2005-05-26 2008-03-07 쉐링 코포레이션 Interferon-IgX Fusion
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2007127949A2 (en) * 2006-04-27 2007-11-08 Sko Flo Industries, Inc. Flow control valve
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
EP2069399A2 (en) * 2007-04-11 2009-06-17 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
BRPI0814363A2 (en) * 2007-07-25 2015-01-27 Biolex Therapeutics Inc INTERFERON CONTROLLED RELEASE DRUG PRODUCTS AND HCV INFECTION TREATMENT USING THE SAME
PT2196475E (en) * 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferon alpha 2a modified by polyethylene glycol, its synthesis process and application
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
UA103492C2 (en) 2008-07-08 2013-10-25 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Inhibitors of proliferacii and activating of vection of signal and activator of transcription (stats)
CN103732242A (en) 2011-06-23 2014-04-16 迪格纳生物技术公司 Treatment of chronic hepatitis C in a patient population with IFN-α5 in combination with IFN-α2b
IN2014DN08236A (en) 2012-03-03 2015-05-15 Immungene Inc
EP2841574A2 (en) * 2012-03-30 2015-03-04 Krishnan, Archana Rajesh Codon optimized sequence for an antiviral protein
CU24554B1 (en) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular FUSION PROTEINS COMPOSED OF INTERLEUKIN 2 MUTEIN AND TYPE 1 INTERFERON

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1215921A (en) 1977-11-08 1986-12-30 Arthur D. Riggs Method and means for microbial polypeptide expression
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
ES479300A1 (en) 1979-04-04 1979-07-01 Cusi Lab An alpha-methyl-4(2'-thienyl-carbonyl)phenyl acetic acid derivative, process for its preparation and its pharmaceutical use.
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4418149A (en) 1980-01-10 1983-11-29 President And Fellows Of Harvard College Fused hybrid gene
US4801685A (en) 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shigekazu N. et al. Synthensin E. coli of a polypeptide with human leukocyte interferon activity. Nature, v. 284, March, 1980, p. 316-320. *

Also Published As

Publication number Publication date
CA1341583C (en) 2008-11-18
KR860001558B1 (en) 1986-10-04
ZW14781A1 (en) 1982-04-21
US6482613B1 (en) 2002-11-19
US6610830B1 (en) 2003-08-26
GEP20074163B (en) 2007-07-10
KR830006422A (en) 1983-09-24

Similar Documents

Publication Publication Date Title
MD430C2 (en) Method for human leucocytar interferone preparation
EP0653940A4 (en) GLOBAL MITOGENIC FACTORS, THEIR PREPARATION AND USE.
MD431C2 (en) Method for leukocytar interferone preparation
DK288183D0 (en) PROCEDURE FOR THE PREPARATION OF AN OLIGONUCLEOTIDE THERAPEUTIC AGENT
KR970000808B1 (en) Human proapolipoprotein a-1 expression
MY101972A (en) Primate interleukin - 4
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DK188582A (en) BACILLUS CLONING VECTORS RECOMBINATION DNA MOLECULES BACILLUS VALUES TRANSFORMED THEREOF, AND PROCEDURES FOR EXPRESSION OF PROCESSED DNA SEQUENCES AND PREPARATION OF POLYPEPTIDES CODED THEREOF
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DE3586697D1 (en) Aktive thymopentin-analoga.
DK54184A (en) DNA SEQUENCES, RECOMBINATION DNA MOLECULES, AND PROCEDURES FOR HUMAN PREPARATION (INTERLEUKIN) TWO SIMILAR POLYPEPTIDES
LTIP1753A (en) Dna sequences coding for proteins, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
FI861653A7 (en) Isolated DNA compound encoding recombinant DNA isopenicillin N synthetase, vectors containing the same and method for producing isopenicillin N synthetase activity therewith
JPS615392B2 (en)
FI961202A0 (en) The Grb3-3 gene, its variants and their uses
GB9215232D0 (en) Vaccines
DK0643719T3 (en) Nucleic acid sequences encoding or complementary to nucleic acid sequences encoding interleukin 9 receptor
ATE215123T1 (en) OR-1, A WAIS RECEPTOR OF THE NUCLEAR RECEPTOR FAMILY
WO1990003394A3 (en) New limphokines, dna sequences coding for said limphokines and pharmaceutical compositions containing said limphokines
IT8521507A0 (en) CLONING VECTOR, RECOMBINANT DNA MOLECULES, STRAINS OF BACILLUS SUBTILIS TRANSFORMED WITH THE SAID MOLECULES AND METHODS FOR THE EXPRESSION OF HETEROLOGOUS GENES AND PRODUCTION AND SECRETION OF PROTEINS CODED BY THE SAID GENES.